Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation

Pharmacological Reports

Volumn 63, Issue 4, 2011, Pages 1029-1039

  Brando Lima, Aline C ^a   Machado, Alexandre L ^a   Simon, Patrícia ^a   Cavalcante, Moisés M ^a   Rezende, Daniele C ^a   Sperandio Da Silva, Gilberto M ^a   Nascimento, Paulo Gustavo B D ^b   Quintas, Luis E M ^a   Cunha, Fernando Q ^b   Barreiro, Eliezer J ^a   Lima, Lídia M ^a   Koatz, Vera L G ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti inflammatory drug candidate; LASSBio 998; Lung inflammation; p38 mitogen activated protein kinase; TNF

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYTOKINE; INTERLEUKIN 1; KERATINOCYTE DERIVED CHEMOKINE; L 998; LASSBIO 998; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; EXPERIMENTAL MODEL; IN VITRO STUDY; IN VIVO STUDY; LOBAR PNEUMONIA; LUNG LAVAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 80053360549     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70619-3     Document Type: Article

References (47)

1. Abraham E: Nuclear factor-κB and its role in sepsis-associated organ failure. J Infect Dis, 2003, 187, S364-S369.
2. Adcock IM, Chung KF, Caramori G, Ito K: Kinase inhibitors and airway inflammation. Eur J Pharmacol, 2006, 533, 118-132. (Pubitemid 43340009)
3. Aimbire F, Penna SC, Rodrigues M, Rodrigues KC, Lopes-Martins RA, Sertié JÁ: Effect of hydroalcoholic extract of Zingiber officinalis rhizomes on LPS-induced rat airway hyperreactivity and lung inflammation. Prostaglandins Leukot Essent Fatty Acids, 2007, 77, 129-138. (Pubitemid 350141684)
4. Aimbire F, Albertine R, De Magalhǎ;es RG, Lopes-Martins RA, Castro-Faria-Neto HC, Zângaro RA, Chavantes MC, Pacheco MT: Effect of LLLT Ga-Al-As (685 nm) on LPS-induced inflammation of the airway and lung in the rat. Lasers Med Sci, 2005, 20, 11-20. (Pubitemid 41175879)
5. Bhatia M., Moochhala S: Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol, 2004, 202, 145-156. (Pubitemid 38208651)
6. Bless NM, Huber-Lang M, Guo RF, Warner RL, Schmal H, Czermak BJ, Shanley TP et al.: Role of CC chemokines (macrophage inflammatory protein-1β, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats. J Immunol, 2000, 164, 2650-2659. (Pubitemid 30115497)
7. 4 mediate the neutrophil migration in immune inflammation. Br J Pharmacol, 2001, 134, 1619-1628.
8. Castro P, Legora-Machado A, Cardilo-Reis L, Valença S, Porto LC, Walker C, Zuany-Amorim C, Koatz VLG: Inhibition of interleukin-1β reduces mouse lung inflammation induced by exposure to cigarette smoke. Eur J Pharmacol, 2004, 498, 279-286. (Pubitemid 39208090)
9. Castro P, Nasser H, Abrahǎ;o A, Dos Reis LC, Rica I, Valença SS, Rezende DC et al.: Aspirin and indomethacin reduce lung inflammation of mice exposed to cigarette smoke. Biochem Pharmacol, 2009, 77, 1029-1039.
10. Chopra P, Kanoje V, Semwal A, Ray A: Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs, 2008, 17, 1411-1425.
11. Cloutier A, Ear T, Blais-Charron E, Dubois CM, Mc Donald PP: Differential involvement of NF-κB and MAP kinase pathways in the generation of inflammatory cytokines by human neutrophils. J Leuk Biol, 2007, 81, 567-577. (Pubitemid 46198409)
12. DiPietro LA, Reintjes MG, Low QE, Levi B, Gamelli RL: Modulation of macrophage recruitment into wounds by monocyte chemoattractant protein-1. Wound Repair Regen, 2001, 9, 28-33. (Pubitemid 32268511)
13. Dominguez C, Powers DA, Tamayo N: p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel, 2005, 8, 421-430. (Pubitemid 40921741)
14. Dumas J, Hatoum-Mokdad H, Sibley R, Riedl B, Scott WJ, Monahan MK, Lowinger TB et al.: 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors. Bioorg Med Chem Lett, 2000, 10, 2051-2054.
15. Esper AM, Martin GS: Evolution of treatments for patients with acute lung injury. Expert Opin Investig Drugs, 2005, 14, 633-645. (Pubitemid 40790284)
16. Garcia-Ramallo E, Marques T, Prats N, Beleta J, Kunkel SL, Godessarti N: Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J Immunol, 2002, 169, 6467-6473. (Pubitemid 36903497)
17. Gonçalves de Moraes VL, Vargaftig B, Lefort J, Meager A, Chignard M: Effect of cyclo-oxygenase inhibitors and modulators of cyclic AMP formation on lipopolysaccharide-induced neutrophil infiltration in mouse lung. Br J Pharmacol, 1996, 117, 1792-1796. (Pubitemid 26121627)
18. Gordon T, Balmes J, Fine J, Sheppard DD: Airway oedema and obstruction in guinea pigs exposed to inhaled endotoxin. Br J Ind Med, 1991, 48, 629-635.
19. Guerrero AT, Verri Jr WA, Cunha TM, Silva TA, Rocha FA, Ferreira SH, Cunha FQ, Parada CA: Hypernociception elicited by tibio-tarsal joint flexion in mice: a novel experimental arthritis model for pharmacological screening. Pharmacol Biochem Behav, 2006, 84, 244-251. (Pubitemid 44137301)
20. Jansson AH, Eriksson C, Wang X: Effects of budesonide and N-acetylcysteine on acute lung hyperinflation, inflammation and injury in rats. Vasc Pharmacol, 2005, 43, 101-111. (Pubitemid 40981938)
21. Je J, Lee JY, Jung KJ, Sung B, Go EK, Yu BP, Chung HY: NF-κB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway. FEBS Lett, 2004, 566, 183-189. (Pubitemid 38656117)
22. Ji RR: Mitogen-activated protein kinases as potential targets for pain killers. Curr Opin Investig Drugs, 2004, 5, 71-75.
23. Keyhanmanesh R, Boskabady MH, Khamneh S, Doostar Y: Effect of thymoquinone on the lung pathology and cytokine levels of ovalbumin-sensitized guinea pigs. Pharmacol Rep, 2010, 62, 910-916.
24. Kim HJ, Lee HS, Chong YH, Kang JL: p38 Mitogen-activated protein kinase up-regulates LPS-induced NF-κB activation in the development of lung injury and RAW264.7 macrophages. Toxicology, 2006, 225, 36-34.
25. Lagente V, Planquois, JM, Leclerc O, Schmidlin F, Bertrand CP: Oxidative stress is an important component of airway inflammation in mice exposed to cigarette smoke or lipopolysaccharide. Clin Exp Pharmacol Physiol, 2008, 35, 601-605. (Pubitemid 351490092)
26. 2-terminal kinase or extracellular signal-regulated kinase improves lung injury. Respir Res, 2004, 5, 23.
27. Lee JC, Young PR: Role of CSBP/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leuk Biol, 1996, 59, 152-157. (Pubitemid 26098701)
28. Lee MR, Dominguez C: MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38α protein. Curr Med Chem, 2005, 12, 2979-2994. (Pubitemid 41672487)
29. Lima LM, Barreiro EJ: Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem, 2005, 12, 23-49. (Pubitemid 40089827)
30. Lima LM, Fraga CAM, Gonçalves-Koatz VL, Barreiro EJ: Thalidomide and analogs as anti-inflammatory and immunomodulator drug candidates. Anti-inflammatory Anti-allergy Agents Med Chem, 2006, 5, 79-95. (Pubitemid 43796733)
31. Liu S, Feng G, Wang G, Liu G: p38 MAPK inhibition attenuates LPS-induced acute lung injury involvement of NF-κB pathway. Eur J Pharmacol, 2008, 584, 159-165.
32. -/- mice. Am J Pathol, 2001, 159, 457-463.
33. Machado AL, Lima LM, Araújo JX, Fraga CA, Koatz VL, Barreiro EJ: Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorg Med Chem Lett, 2005, 15, 1169-1172. (Pubitemid 40467439)
34. Mihara K, Almansa C, Smeets RL, Loomans EE, Dulos J, Vink PM, RooseboomMet al.: Apotent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNF-α. Br J Pharmacol, 2008, 154, 153-164. (Pubitemid 351620394)
35. Nagahira A, Nagahira K, Murafuji H, Abe K, Magota K, Matsui M, Oikawa S: Identification of a novel inhibitor of LPS-induced TNF-α production with antiproliferative activity in monocyte/macrophages. Biochem Biophys Res Commun, 2001, 281, 1030-1036. (Pubitemid 32917836)
36. Nick JA, Young SK, Arndt PG, Lieber JG, Suratt BT, Poch KR, Avdi NJ, et al.: Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol, 2000, 164, 2151-2159. (Pubitemid 30108774)
37. Nick JA, Young SK, Brown KK, Avdi NJ, Arndt PG, Suratt BT, Janes MS et al.: Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J Immunol, 2002, 169, 5260-5269. (Pubitemid 35217198)
38. Raghavendran K, Pryhuber GS, Chess PR, Davidson BA, Knight PR, Notter RH: Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem, 2008, 15, 1911-1924.
39. Redman AM, Johnson JS, Dally R, Swartz S, Wild H, Paulsen H, Caringal Y et al.: p38 Kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas. Bioorg Med Chem, 2001, 11, 9-12. (Pubitemid 32006113)
40. Shireman PK, Contreras-Shannon V, Ochoa O, Karia BP, Michalek JE, McManus LM: MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration. J Leuk Biol, 2007, 81, 775-785. (Pubitemid 46393555)
41. Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Hayward TK, Higgins LS, Giembycz MAet al.: Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol, 2006, 149, 393-404. (Pubitemid 44582246)
42. Sperandio da Silva GM, Sant'Anna CM, Barreiro EJ: A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. Bioorg Med Chem, 2004, 12, 3159-3166. (Pubitemid 38680705)
43. Sugiyama K-I, Muroi M, Tanamoto K-I: A novel TLR4-binding peptide that inhibits LPS induced activation of NF-κB and in vivo toxicity. Eur J Pharmacol, 2008, 594, 152-156.
44. Ulich TR, Yi ES, Smith C, Remick D: Intratracheal administration of endotoxin and cytokines VII. The soluble interleukin-1 receptor and the soluble tumor necrosis factor receptor II (p80) inhibit acute inflammation. Clin Immunol Immunopathol, 1994, 72, 137-140. (Pubitemid 24227347)
45. Vieira SM, Lemos HP, Grespan R, Napimoga MH, Dal-Secco D, Freitas A, Cunha TM et al.: A crucial role for TNF-α in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br J Pharmacol, 2009, 158, 779-789.
46. Zhou HY, Shin EM, Guo LY, Youn UJ, Bae K, Kang SS, Zou LB, Kim YS: Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW264.7 macrophages via NF-κB, JNK and p38 MAPK inactivation. Eur J Pharmacol, 2008, 586, 340-349.
47. Zhou LH, Tu SJ, Shi DQ, Dai GY, Chen WX: Lowvalent titanium induced novel reductive cyclizations of α,β-unsaturated nitrile compounds. Synthesis (Stuttgart), 1998, 6, 851-854.